Drug
Ruxolitinib clinical trials
Also written Jakafi, INCB018424, INCB18424 and Jakavi.
Keep track of what changes. Save the ruxolitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Ruxolitinib
- 223
Development codes
- INC424
- 25
Studies by the year they started
323 studies that test it; most in 2026 (28); 1 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 21 |
| 2015 | 14 |
| 2016 | 15 |
| 2017 | 20 |
| 2018 | 19 |
| 2019 | 21 |
| 2020 | 26 |
| 2021 | 21 |
| 2022 | 18 |
| 2023 | 24 |
| 2024 | 23 |
| 2025 | 27 |
| 2026 | 28 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 113 · Other 211
Incyte Corporation (72) · Novartis Pharmaceuticals (23) · M.D. Anderson Cancer Center (17) · Memorial Sloan Kettering Cancer Center (9) · Institute of Hematology & Blood Diseases Hospital, China (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Fred Hutchinson Cancer Center (5) · AbbVie (5)
Often tested with
Tested in the same studies.
Cyclophosphamide (10) · Dexamethasone (7) · Methotrexate (7) · Dasatinib (6) · Sirolimus (5) · Tacrolimus (5) · Decitabine (5) · Panobinostat (4)
Studies
Open first, then newest update. How each study uses ruxolitinib is read from its arms, and is right about nine times in ten.
Testing it · 324
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05398809Written as Ruxolitinib
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02974647Written as Ruxolitinib
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingPhase 3Incyte CorporationNCT06615050Written as Ruxolitinib (Rux)
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07588945Written as Ruxolitinib
- Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingPhase 2University Hospital, Basel, SwitzerlandNCT07840456Written as Ruxolitinib
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingPhase 2/3Bambino Gesù Hospital and Research InstituteNCT07297914Written as Ruxolitinib
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as Ruxolitinib
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingPhase 1University of UtahNCT07521046Written as Ruxolitinib
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT06128070Written as Ruxolitinib Phosphate
- Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingEarly Phase 1Baylor Research InstituteNCT06008275Written as Ruxolitinib Oral Tablet
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoRecruitingPhase 3Incyte CorporationNCT06804811Written as Ruxolitinib Cream
- Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07128381Written as Ruxolitinib
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingPhase 1Incyte CorporationNCT07049575Written as Ruxolitinib Cream
- Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumRecruitingPhase 2Oregon Health and Science UniversityNCT07783412Written as topical ruxolitinib 1.5% cream
- A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsRecruitingPhase 1Damora TherapeuticsNCT07849231Written as Ruxolitinib
- Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell TransplantationRecruitingPhase 1OHSU Knight Cancer InstituteNCT07548983Written as Ruxolitinib
- Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)Not yet recruitingPhase 2Dennis KimNCT07643025Written as Ruxolitinib
- Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed GlioblastomaRecruitingPhase 2Baptist Health South FloridaNCT06991101Written as Ruxolitinib
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic LeukemiaRecruitingPhase 2Jonathan BrammerNCT05592015Written as Ruxolitinib
- Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationRecruitingPhase 1City of Hope Medical CenterNCT07025538Written as Ruxolitinib
See all 324 studies that test ruxolitinib →
Given in every arm · 42 — ruxolitinib is usual care beside what is tested
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)RecruitingPhase 3Novartis PharmaceuticalsNCT07357727Written as Ruxolitinib
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Ruxolitinib
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04176198Written as Ruxolitinib
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingPhase 1Janssen Research & Development, LLCNCT06150157Written as Ruxolitinib
- Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1Jennifer SaultzNCT03874052Written as Ruxolitinib
- Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host DiseaseRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT04744116Written as Ruxolitinib
- RVU120 Rollover StudyEnrolling by invitationPhase 2Ryvu Therapeutics SANCT06987058Written as Ruxolitinib
- Revumenib in Patients With MyelofibrosisNot yet recruitingPhase 1/2John MascarenhasNCT07734077Written as Ruxolitinib
- Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07184853Written as Ruxolitinib (JAKAVI®)
- Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHDNot yet recruitingPhase 4Peking University People's HospitalNCT06364319Written as Ruxolitinib
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingPhase 1Mayo ClinicNCT03017820Written as Ruxolitinib
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06327100Written as Ruxolitinib
- Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationRecruitingPhase 1Washington University School of MedicineNCT06008808Written as Ruxolitinib
- MAGIC Ruxolitinib for aGVHDRecruitingPhase 2John LevineNCT06936566Written as Ruxolitinib
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Ruxolitinib
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibRecruitingPhase 3Kartos Therapeutics, Inc.NCT06479135Written as Ruxolitinib
- Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus ErythematosusRecruitingPhase 2Innovaderm Research Inc.NCT06261021Written as Ruxolitinib 1.5% cream
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingEarly Phase 1OncotherapeuticsNCT06209606Written as Ruxolitinib Oral Tablet [Jakafi]
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingPhase 1OncotherapeuticsNCT03110822Written as Ruxolitinib Oral Tablet [Jakafi]
- Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisActive, not recruitingPhase 3Karyopharm Therapeutics IncNCT04562389Written as Ruxolitinib
Showing 20 of 42.
As the comparator · 12 — what is tested is compared with ruxolitinib
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07722611Written as Ruxolitinib
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisRecruitingPhase 3Chengdu Zenitar Biomedical Technology Co., LtdNCT07317700Written as Ruxolitinib Phosphate
- BeFluBu vs FluBuRux Conditioning in Haploidentical HCTRecruitingPhase 2St. Petersburg State Pavlov Medical UniversityNCT06477549Written as Ruxolitinib
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Ruxolitinib
- A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk MyelofibrosisActive, not recruitingPhase 2Chengdu Zenitar Biomedical Technology Co., LtdNCT06457425Written as Ruxolitinib
- A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic DermatitisCompletedPhase 2CAGE Bio Inc.NCT06923228Written as Ruxolitinib 1.5% Cream QD
- Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor AvailabilityActive, not recruitingPhase 2Universitätsklinikum Hamburg-EppendorfNCT03333187Written as Ruxolitinib continuous therapy
- A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.CompletedPhase 1Taro Pharmaceuticals USANCT06673654Written as OPZELURA (Ruxolitinib) Cream
- A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)TerminatedPhase 3XenikosNCT04934670Written as Ruxolitinib
- Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedPhase 3Sierra Oncology LLC - a GSK companyNCT01969838Written as Ruxolitinib
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraStatus unknownPhase 2Kartos Therapeutics, Inc.NCT03669965Written as Ruxolitinib
- Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedPhase 1Concert PharmaceuticalsNCT02960945Written as Jakafi 15Mg Tablet
Codes
What other systems call ruxolitinib · ClinicalTrials.gg INT005425
- MeSH (NLM) C540383ruxolitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 82S8X8XX8HRUXOLITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1193326Confirmed FDA, Wikidata
- Wikidata Q7383611ruxolitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77888RuxolitinibOne source FDA
- DrugBank DB08877One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C540383 | ruxolitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 82S8X8XX8H | RUXOLITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1193326 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7383611 | ruxolitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77888 | Ruxolitinib | One source FDA |
| DrugBank | DB08877 | — | One source Wikidata |
Also registered as ruxolitinib phosphate (UNII 436LRU32H5 · RxNorm 1193325).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.